Bristol-Myers Squibb to acquire AstraZeneca in deal valued at $400 billion

Bristol-Myers Squibb agreed to acquire AstraZeneca in an all-cash transaction valued at $400 billion. AstraZeneca is a multinational biopharmaceutical company that develops, manufactures, and commercializes prescription medications across oncology, cardiovascular, respiratory, and immunology. The transaction is subject to customary closing conditions and regulatory approvals.